Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

BACKGROUND: Dyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not well understood. We aimed to explore the association between apolipoprotein A1 (ApoA1) and B (ApoB) and cardiovascular events in patients w...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Am Heart Assoc
Päätekijät: Pol, Tymon, Held, Claes, Westerbergh, Johan, Lindbäck, Johan, Alexander, John H., Alings, Marco, Erol, Cetin, Goto, Shinya, Halvorsen, Sigrun, Huber, Kurt, Hanna, Michael, Lopes, Renato D., Ruzyllo, Witold, Granger, Christopher B., Hijazi, Ziad
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2018
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5850246/
https://ncbi.nlm.nih.gov/pubmed/29419390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.007444
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia